Imagenetix, Inc (IAGX) Fair Value & Analysis
Healthcare · US · Market cap $2.8K
Imagenetix, Inc
IAGX · US
Fair value as of: Jun 26, 2026
From 6 valuation models · updated 7 days ago
Fair value updated Jun 26, 2026 — revised from $0.0100 to $0.0001 (−99.0%) since Jun 24, 2026.
Price vs Fair Value (12 months)
12‑month range $0.0001 – $0.0001 · the $0.0001 price screens below the $0.0001 fair value. As of Jun 26, 2026.
✦ Which stocks are undervalued right now? Check free Discover now →Analysis
Imagenetix, Inc (IAGX) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001 — implying the stock looks roughly 0.0% undervalued today. We read business quality at 40/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low) — always confirm before acting.
Key figures & financial health
Figures from reported company fundamentals (EODHD) · as of Jun 26, 2026. TTM = trailing twelve months.
About the company
Imagenetix, Inc. engages in the research, development, and commercialization of compositions to reduce body fat and enhance overall body composition. It offers an inference engine for CT, MRI, and X ray studies, a clinician review workstation that surfaces model outputs within the diagnostic viewer, and an enterprise analytics hub for quality and utilization reporting. The company was founded in 1996 and is based in San Diego, California.
Revenue & earnings trend
FY2008 – FY2015 · reported fiscal years
Imagenetix, Inc reported revenue of $824K in FY2015 versus $5.6M in FY2008, a compound −23.9%/yr. Reported net income was −$21.7K in FY2015.
Is IAGX fairly valued? → Check now
Similar stocks
6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jun 26, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Jiangsu Hengrui Pharmaceuticals Co 1276 | HK$57.85 | HK$29.84 | -48% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,782 | ₹915.92 | -49% |
| Zoetis Inc Z1TS34 | R$26.19 | R$26.01 | -1% |
| Hansoh Pharmaceutical Group 3692 | HK$29.58 | HK$18.75 | -37% |
| Divi's Laboratories Limited DIVISLAB | ₹6,788 | ₹2,035 | -70% |
| Swedish Orphan Biovitrum AB SOBI | kr 435.00 | kr 285.77 | -34% |
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Imagenetix, Inc (IAGX) undervalued?
What is the fair value of IAGX?
What is the quality score of IAGX?
What is the net profit margin of IAGX?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.
Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.